Multiple Myeloma in Relapse Not Yet Recruiting Phase 2 Trials for Daratumumab (DB09331)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03697629A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple MyelomaTreatment